title: The special case of gene therapy pricing.
abstract: Gene therapy companies that pursue high, one-time payments for their products risk a backlash from payors. A better solution may lie in a pay-for-performance model.
authors.affiliation: CVS Caremark, Woonsocket, Rhode Island, USA.
authors.forename: Troyen A
authors.initials: TA
authors.lastname: Brennan
authors.affiliation: Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
authors.forename: James M
authors.initials: JM
authors.lastname: Wilson
mesh_terms: D015316:Genetic Therapy / Q000191:economics*; D006801:Humans; D012051:Reimbursement Mechanisms